AeroPace System
Commercial- Indications
- Mechanical ventilation weaning
Company intelligence / Profile preview
The AeroPace System received FDA premarket approval in December 2024 for improving weaning success in adult patients on mechanical ventilation ≥96 hours who have not weaned. Clinical data show significant reduction in ventilator days and reintubation rates. The investigational AeroNova System has entered a Phase 2 feasibility study targeting acute hypoxemic respiratory failure with the goal of reducing multi-organ ventilator-induced injury.
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Lungpacer Medical.